Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Despite significant advances in the treatment of cervical, ovarian, and uterine cancers with
the approvals of checkpoint and PARP inhibitors into standard treatment, patients with …

Antibody-drug conjugates (ADCs) provide effective cancer treatment through the selective
delivery of cytotoxic payloads to the cancer cells. They offer unparalleled precision and …

ImmunoGen developed mirvetuximab soravtansine as an antibody–drug conjugate
comprising of a humanized anti-folate receptor—α (FRα) monoclonal antibody of IgG1 k …

Simple Summary Despite all the efforts and advances made in the treatment of breast
cancer, this pathology continues to be one of the main causes of cancer death in women …

Microtubules are pivotal in diverse cellular functions encompassing cell signaling,
morphology, intracellular trafficking, and cell mitosis/division. They are validated targets for …

Antibody-drug conjugates (ADCs) are a growing class of chemotherapeutic agents for the
purpose of treating cancers that often have relapsed or failed first-and second-line …

Objective To evaluate the efficacy and safety of mirvetuximab soravtansine in treating
recurrent ovarian cancer with folate receptor alpha (FRa) expression. Methods A …

Simple Summary The fact that most endometrial cancer (EC) patients overexpress the
CXCR4 receptor in tumor tissue, especially at incurable advanced stages, opens an avenue …

Background: Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has
raised global concern. Although several papers have reviewed the current state of ADCs in …